# Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms

> **NCT00703534** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 478 (actual)

## Conditions studied

- GERD
- Acid Reflux Disease
- Heartburn
- Regurgitation

## Interventions

- **DRUG:** AZD3355
- **DRUG:** Placebo
- **DRUG:** Gelusil®

## Key facts

- **NCT ID:** NCT00703534
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2011-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00703534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00703534, "Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00703534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*